Evidence map›Paper›PMID 42143596›Full record

ArticleThe journal of sexual medicine2026

Prevalence and predictors of bone density loss in men with low testosterone.

Jose M Flores, Nicole Liso, John P Mulhall

Abstract read
In one paragraph

Article in The journal of sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jose M FloresSexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.ORCID 0000-0002-8912-7037
Nicole LisoDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
John P MulhallSexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.ORCID 0000-0001-5455-3047

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
National Cancer Institute to Memorial Sloan Kettering Cancer CenterNCI NIH HHS P30 CA008748Sidney Kimmel Center for Prostate and Urologic Cancers and the National Institutes of Health
6 · The paper itself

Abstract

backgroundLow testosterone (T) is associated with several sequelae, including a high prevalence of bone density loss (BDL).

aimWe aimed to identify predictors of BDL in men with low T.

methodsThe sample included (1) men ≥50 years old, (2) with low total T levels (<300 ng/dL using LCMS on 2 early morning blood draws), (3) who had dual-energy X-ray absorptiometry (DEXA) within 6 months of T measurement. Men with prior T therapy were excluded. On DEXA, osteopenia was defined as a T score between -1.0 and -2.5, and osteoporosis as a T score below -2.5. Additionally, demographics and comorbidity data were collected. We report BDL rates and identify predictors of any BDL using logistic regression. OUTCOMES: Bone density loss, which was defined as the presence of osteopenia or osteoporosis.

resultsNine hundred ninety-seven men were analyzed, with a median age of 64 (IQR 59, 70) years. Median total T was 202 (IQR: 107, 256) ng/dL, median free T 5.8 (IQR: 4.3, 7.5) ng/dL. 24% had a total T ≤ 100 ng/dL. Thirty-three percent had ≥3 comorbidities. Seventy-four percent of our cohort had an oncological history; most of them had a history of prostate cancer. Bone density loss was present in 36% of the patients (89% osteopenia, 11% osteoporosis). On multivariable analysis, significant predictors of BDL were lower total T levels (OR = 1.09), older age (OR = 1.59), and the presence of ≥3 comorbidities (OR = 1.60). CLINICAL IMPLICATIONS: It is critical to be aware of the significant prevalence of BDL in men with low T. Early identification may enable targeted counseling, the initiation of preventive or therapeutic strategies to improve bone density outcomes, and the reduction of the risk of fractures and other serious skeletal complications. STRENGTHS & LIMITATIONS: Limitations related to retrospective design, including selection bias and unmeasured confounding factors. Another limitation is that most cases had an oncological history. However, several strengths include the use of a large, systematically audited database; T labs were assessed using gold-standard methodology; and bone mineral density was assessed using a standardized scanning protocol.

conclusionIn our cohort of older men, most with oncological history and low T, around one-third had BDL, and around 10% of those with BDL had osteoporosis. Lower T levels, older age, and a greater number of comorbidities were significant predictors of BDL.

Indexed as

Bone DensityBone Diseases, MetabolicOsteoporosisTestosteroneAbsorptiometry, PhotonAgedHumansMaleMiddle AgedPrevalenceRisk FactorsTestosteronebone density losslow testosteroneosteopeniaosteoporosis

Identifiers

PMID42143596
PMCPMC13484939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.